Baidu
map

J Stroke Cerebrovasc Dis:大血管硬化卒中患者的病理生理机制与预后

2015-08-20 phylis 译 MedSci原创

背景:缺血性脑卒中的病理学机制在长期预后的判断中起着重要的作用。我们主要调查由于大血管因素引起卒中的机制和长期预后之间的关系。方法:招募1993年-2010年间在雅典卒中登记的卒中患者,这些患者存在动脉粥样硬化。根据不同的发病机制,将病人分为3组:低血流量性梗塞,动脉栓子以及固有动脉粥样硬化组。随访时间长达10年或者直到死亡。研究的终点:10年死亡率,卒中再发率以及各种心血管事件的发生。结果:50

背景:缺血性脑卒中的病理学机制在长期预后的判断中起着重要的作用。我们主要调查由于大血管因素引起卒中的机制和长期预后之间的关系。

方法:招募1993年-2010年间在雅典卒中登记的卒中患者,这些患者存在动脉粥样硬化。根据不同的发病机制,将病人分为3组:低血流量性梗塞,动脉栓子以及固有动脉粥样硬化组。随访时间长达10年或者直到死亡。研究的终点:10年死亡率,卒中再发率以及各种心血管事件的发生。

结果:502名患者如下分组:156(31%)患者低血流量梗死,256 (51%) 患者动脑栓子梗塞,90 (18%)患者固有动脉粥样硬化。不同的梗死机制,10年的累积死亡率没有差异:低血流量组49.9% (95% CI, 38.5-61.3);动脉栓塞组47.6% (95% CI, 39.4-55.8);动脉粥样硬化组48.5% (95% CI, 34.0-63.0)。与动脉栓塞组患者,动脉粥样硬化组的患者的卒中再发率较高(HR = 2.1; 95% CI, 1.19-3.73)。与动脉栓塞组相比,动脉粥样硬化组和低血流量组患者的心血管事件发生率较高(HR 分别为1.94、1.64; 95% CI分别为 1.26-3.00,1.13-2.38)。

结论:低血流量组和动脉粥样硬化组卒中与未来心血管事件的发生和卒中的再发相关。然而,各组长期死亡率是相同的。

原文出处:

Psychogios K, Stathopoulos P, Takis K,et al. The Pathophysiological Mechanism Is an Independent Predictor of Long-Term Outcome in Stroke Patients with Large Vessel Atherosclerosis. J Stroke Cerebrovasc Dis. 2015 Aug 14. 


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938506, encodeId=041b1938506be, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Mar 30 12:46:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012005, encodeId=011c201200545, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 03 21:46:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691258, encodeId=8045169125838, content=<a href='/topic/show?id=378089e311a' target=_blank style='color:#2F92EE;'>#血管硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89731, encryptionId=378089e311a, topicName=血管硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fae529209097, createdName=jiyangfei, createdTime=Tue May 31 00:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720048, encodeId=7fde1e2004898, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Feb 22 10:46:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701760, encodeId=a53c1e0176085, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Nov 17 22:46:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706101, encodeId=dd871e06101a9, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Sun Sep 13 15:46:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36057, encodeId=31963605e8b, content=我喜欢我喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Tue Aug 25 14:26:00 CST 2015, time=2015-08-25, status=1, ipAttribution=)]
    2016-03-30 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1938506, encodeId=041b1938506be, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Mar 30 12:46:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012005, encodeId=011c201200545, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 03 21:46:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691258, encodeId=8045169125838, content=<a href='/topic/show?id=378089e311a' target=_blank style='color:#2F92EE;'>#血管硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89731, encryptionId=378089e311a, topicName=血管硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fae529209097, createdName=jiyangfei, createdTime=Tue May 31 00:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720048, encodeId=7fde1e2004898, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Feb 22 10:46:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701760, encodeId=a53c1e0176085, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Nov 17 22:46:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706101, encodeId=dd871e06101a9, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Sun Sep 13 15:46:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36057, encodeId=31963605e8b, content=我喜欢我喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Tue Aug 25 14:26:00 CST 2015, time=2015-08-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1938506, encodeId=041b1938506be, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Mar 30 12:46:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012005, encodeId=011c201200545, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 03 21:46:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691258, encodeId=8045169125838, content=<a href='/topic/show?id=378089e311a' target=_blank style='color:#2F92EE;'>#血管硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89731, encryptionId=378089e311a, topicName=血管硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fae529209097, createdName=jiyangfei, createdTime=Tue May 31 00:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720048, encodeId=7fde1e2004898, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Feb 22 10:46:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701760, encodeId=a53c1e0176085, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Nov 17 22:46:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706101, encodeId=dd871e06101a9, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Sun Sep 13 15:46:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36057, encodeId=31963605e8b, content=我喜欢我喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Tue Aug 25 14:26:00 CST 2015, time=2015-08-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1938506, encodeId=041b1938506be, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Mar 30 12:46:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012005, encodeId=011c201200545, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 03 21:46:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691258, encodeId=8045169125838, content=<a href='/topic/show?id=378089e311a' target=_blank style='color:#2F92EE;'>#血管硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89731, encryptionId=378089e311a, topicName=血管硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fae529209097, createdName=jiyangfei, createdTime=Tue May 31 00:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720048, encodeId=7fde1e2004898, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Feb 22 10:46:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701760, encodeId=a53c1e0176085, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Nov 17 22:46:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706101, encodeId=dd871e06101a9, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Sun Sep 13 15:46:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36057, encodeId=31963605e8b, content=我喜欢我喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Tue Aug 25 14:26:00 CST 2015, time=2015-08-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1938506, encodeId=041b1938506be, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Mar 30 12:46:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012005, encodeId=011c201200545, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 03 21:46:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691258, encodeId=8045169125838, content=<a href='/topic/show?id=378089e311a' target=_blank style='color:#2F92EE;'>#血管硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89731, encryptionId=378089e311a, topicName=血管硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fae529209097, createdName=jiyangfei, createdTime=Tue May 31 00:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720048, encodeId=7fde1e2004898, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Feb 22 10:46:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701760, encodeId=a53c1e0176085, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Nov 17 22:46:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706101, encodeId=dd871e06101a9, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Sun Sep 13 15:46:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36057, encodeId=31963605e8b, content=我喜欢我喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Tue Aug 25 14:26:00 CST 2015, time=2015-08-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1938506, encodeId=041b1938506be, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Mar 30 12:46:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012005, encodeId=011c201200545, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 03 21:46:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691258, encodeId=8045169125838, content=<a href='/topic/show?id=378089e311a' target=_blank style='color:#2F92EE;'>#血管硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89731, encryptionId=378089e311a, topicName=血管硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fae529209097, createdName=jiyangfei, createdTime=Tue May 31 00:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720048, encodeId=7fde1e2004898, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Feb 22 10:46:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701760, encodeId=a53c1e0176085, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Nov 17 22:46:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706101, encodeId=dd871e06101a9, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Sun Sep 13 15:46:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36057, encodeId=31963605e8b, content=我喜欢我喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Tue Aug 25 14:26:00 CST 2015, time=2015-08-25, status=1, ipAttribution=)]
    2015-09-13 kkunny
  7. [GetPortalCommentsPageByObjectIdResponse(id=1938506, encodeId=041b1938506be, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Mar 30 12:46:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012005, encodeId=011c201200545, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 03 21:46:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691258, encodeId=8045169125838, content=<a href='/topic/show?id=378089e311a' target=_blank style='color:#2F92EE;'>#血管硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89731, encryptionId=378089e311a, topicName=血管硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fae529209097, createdName=jiyangfei, createdTime=Tue May 31 00:46:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720048, encodeId=7fde1e2004898, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Feb 22 10:46:00 CST 2016, time=2016-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701760, encodeId=a53c1e0176085, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Nov 17 22:46:00 CST 2015, time=2015-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706101, encodeId=dd871e06101a9, content=<a href='/topic/show?id=7f6443986ec' target=_blank style='color:#2F92EE;'>#大血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43986, encryptionId=7f6443986ec, topicName=大血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caff31165455, createdName=kkunny, createdTime=Sun Sep 13 15:46:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36057, encodeId=31963605e8b, content=我喜欢我喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Tue Aug 25 14:26:00 CST 2015, time=2015-08-25, status=1, ipAttribution=)]
    2015-08-25 快乐晴天

    我喜欢我喜欢

    0

相关资讯

Lancet:去氨普酶治疗重度缺血性卒中后3-9h安全性和有效性评估

目前溶栓治疗缺血性卒中发病后限制为3〜4.5小时。我们的目的是评估去氨普酶的安全性和有效性,一种纤维蛋白依赖性纤溶酶原激活剂,在主要脑动脉患者闭塞或重度狭窄症状出现后3-9小时治疗。    在一项前瞻性,双盲,多中心,平行组,随机试验中,我们从17个国家77家医院招募那些曾在大型脑动脉缺血性脑卒中和闭塞或重度狭窄的患者参加试验。我们随机分配患者以1:1的比例,使用计算

Stroke:血液透析患者缺血性卒中的发病率和病死率较高

    终末期肾病(ESRD)需要血液透析治疗,但该治疗方法比正常肾功能增加了10倍脑卒中的风险。来自一般人群的危险因素和管理策略的知识可能并不适用于这些终末期肾病患者。研究人员进行了一项大规模终末期肾病人群的研究来确定脑卒中的风险因素和预后。       从2007年1月1日到2012年12月31日所有接受血液透析的ESRD成年患者参与

荟萃分析:缺血性卒中早期降压治疗的作用

缺血性卒中急性期血压升高常见,相关治疗策略尚未确定,因此台湾学者开展了一项随机对照研究的荟萃分析,探讨了缺血性卒中早期积极降压治疗的有效性。 研究者们检索了Pubmed、EMBASE和“Clinicaltrials.gov”数据库,纳入了缺血性卒中发病3天内降压治疗与对照组相比较的随机对照研究。主要转归为3个月或试验终点(功能依赖或死亡)时的不良结

Circulation:缺血性卒中患者出院后服用他汀类药物临床效果显著

在缺血性卒中患者中,他汀类药物治疗的临床真实有效性数据和以病人为中心的结果对于更好地信息共享决策是必要的。PROSPER是PCORI资助卒中幸存者的研究计划,旨在评估卒中后治疗的有效性。该研究对GWTG® - 卒中注册医疗保险索赔中≥65岁的患者数据进行了分析。研究人员对那些出院后使用他汀类药物和没有进行调整的出院后两年的结果采用逆概率加权进行分析。主要终点是:1)主要心血管不良事件(MACE);

ISC 2015:卒中急性期治疗应思考的七件事

编者按 时间就是大脑,卒中急性期治疗医生应注意哪些问题?美国当地时间2月11日1:35pm~2:45pm国际卒中大会(ISC)现场,7位专家从疗效、疗法、时间窗、规范化、安全性、患者转运以及卫生经济学7个方面对该问题进行剖析。如何治疗有效、治疗时机如何把控、如何评判临床数据准确性、如何兼顾治疗安全性、怎样让更多患者从中获益,都是需医生思考的重要问题。  1、治疗有效性和时间窗

ISC 2015:早期血管内治疗可降缺血性卒中患者死亡率(ESCAPE试验)

加拿大一项研究表明,在近端血管闭塞的缺血性卒中患者中,早期血管内介入治疗可改善功能转归并降低死亡率。论文2月11日在线发表于《新英格兰医学杂志》(N Engl J Med)。研究于2015年国际卒中大会(ISC2015)上发布。 此项III期试验名为ESCAPE研究,共纳入316例伴有大动脉闭塞的缺血性卒中患者,并随机给予包括tPA在内的标准治疗或标准治疗联合血管内介入。血管内治

Baidu
map
Baidu
map
Baidu
map